Heparin‐induced Thrombocytopenia with Thrombosis in COVID‐19 Adult Respiratory Distress Syndrome
ISTH Academy. R. Riker R. 05/20/20; 303289
Richard R. Riker
Contributions
Contributions
Journal Abstract
Abstract
Early reports of COVID‐19 clinical features describe a hypercoagulable state, and recent guidelines recommend prophylactic anticoagulation for COVID‐19 patients with low molecular weight heparin, but this would be contraindicated in the presence of heparin‐induced thrombocytopenia (HIT). We address the key clinical question whether HIT is also present during COVID‐19. We report 3 cases of thrombocytopenia with anti‐platelet factor 4 antibodies among 16 intubated COVID‐19 patients with adult respiratory distress syndrome, a higher than expected incidence of 19%. Each patient had evidence of thrombosis (pulmonary embolism, upper extremity venous thromboses, and skin necrosis, respectively). The serotonin release assay confirmed HIT in one case, and two cases were negative. We believe this is the first reported case of HIT during the COVID‐19 pandemic. Recognition that the thrombocytopenia represented HIT in the confirmed case was delayed. We recommend clinicians monitor platelet counts closely during heparin therapy, with a low threshold to evaluate for HIT.
Early reports of COVID‐19 clinical features describe a hypercoagulable state, and recent guidelines recommend prophylactic anticoagulation for COVID‐19 patients with low molecular weight heparin, but this would be contraindicated in the presence of heparin‐induced thrombocytopenia (HIT). We address the key clinical question whether HIT is also present during COVID‐19. We report 3 cases of thrombocytopenia with anti‐platelet factor 4 antibodies among 16 intubated COVID‐19 patients with adult respiratory distress syndrome, a higher than expected incidence of 19%. Each patient had evidence of thrombosis (pulmonary embolism, upper extremity venous thromboses, and skin necrosis, respectively). The serotonin release assay confirmed HIT in one case, and two cases were negative. We believe this is the first reported case of HIT during the COVID‐19 pandemic. Recognition that the thrombocytopenia represented HIT in the confirmed case was delayed. We recommend clinicians monitor platelet counts closely during heparin therapy, with a low threshold to evaluate for HIT.
{{ help_message }}
{{filter}}